How to invest in the fight against cancer

A new generation of anti-cancer drugs looks promising. There are four main ways to invest, with varying levels of risk. Dr Michael Tubbs explains.

864_MW_P32_analysis

Basel, home to Roche and Novartis the most promising of the big pharma companies
(Image credit: Credit: Georgios Tsichlis / Alamy Stock Photo)

A new generation of anti-cancer drugs looks promising. There are four main ways to invest, with varying levels of risk. Dr Michael Tubbs explains.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Swipe to scroll horizontally
CompanyOncologyrev. (2016)Comment
Roche$26.4bnProbably has the largest pipeline of oncology drugs (includes trials of Tecentriq for additional cancers)
Celgene$10.1bnSpecialises in blood cancers and is partnering with AstraZeneca on Imfinzi for blood cancers
Novartis$9.3bnWell placed for CAR-T immunotherapy (eg, Kymriah)
Bristol-Myers Squibb$6.9bnOpdivo and Yervoy immunotherapies already approved
Johnson & Johnson$5.0bnFDA approved Darzalex immunotherapy for multiple myeloma in late 2016
Dr Mike Tubbs

Highly qualified (BSc PhD CPhys FInstP MIoD) expert in R&D management, business improvement and investment analysis, Dr Mike Tubbs worked for decades on the 'inside' of corporate giants such as Xerox, Battelle and Lucas. Working in the research and development departments, he learnt what became the key to his investing; knowledge which gave him a unique perspective on the stock markets.

Dr Tubbs went on to create the R&D Scorecard which was presented annually to the Department of Trade & Industry and the European Commission. It was a guide for European businesses on how to improve prospects using correctly applied research and development. He has been a contributor to MoneyWeek for many years, with a particular focus on R&D-driven growth companies.